Citizens' views on prices of medicines reimbursed by the National Health Service: Findings from Italian online focus groups
- PMID: 38432872
- PMCID: PMC10909621
- DOI: 10.1111/hex.14005
Citizens' views on prices of medicines reimbursed by the National Health Service: Findings from Italian online focus groups
Abstract
Introduction: Access to medicines is one of the biggest challenges to health systems, affecting society and individuals. This study aims to explore citizens' opinions, perceptions and attitudes on the model of medicines' research and development (R&D) and price setting of medicines reimbursed by the Italian National Health Service.
Materials and methods: We run four online focus groups, analysed through thematic analysis.
Inclusion criteria: people aged 30-70 years, who had completed at least compulsory schooling (8-10 years), with no specialised knowledge about the subject.
Exclusion criteria: healthcare workers, pharmaceutical and device industry employees, researchers and medicine policy board members. We aimed to include a purposive sample of 20 participants, variable in terms of age, educational level and place of residence.
Results: Eleven women and six men participated. The mean age was 53 years (range: 28-73). Most (n = 15) had a university degree or attended secondary schools. Eight had a job, five were not employed, and four were retired. In general, participants supported the role of the public health service. Almost all had limited knowledge of medicines' R&D and price setting. Most asked for transparency on medicine prices and negotiation criteria. Participants considered revenues of pharmaceutical companies disproportionate and most called for containment measures of profits. Most were in favour of a stronger public intervention in R&D and prices' negotiations. Few were sceptical of the public sector's ability to play this role.
Discussion: Medicines' prices were discussed as a health matter. Increasing citizens' awareness of these topics is needed by providing spaces and conditions to participate in the discussion, including different perspectives and interests.
Patient or public contribution: Members of BEUC-the European consumer organisation-proposed the project. Altroconsumo, an independent consumer organisation and OCU, a Spanish consumer organisation, participated in developing the project and the main topics to discuss. The Mario Negri Institute and Aplica cooperative-the Spanish methodological team-were involved by BEUC and their national organisations to define the methodology, organisational aspects and contents and conducted the focus groups.
Keywords: National Health Service; citizen; focus groups; medicines' access; medicines' price; public health.
© 2024 The Authors. Health Expectations published by John Wiley & Sons Ltd.
Conflict of interest statement
Cinzia Colombo and Rita Banzi have no conflicts of interest. Daniele Caldara works for Altroconsumo—Independent consumer organisation—funder of the study.
Similar articles
-
Price comparison of high-cost originator medicines in European countries.Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):221-230. doi: 10.1080/14737167.2016.1223543. Epub 2016 Oct 11. Expert Rev Pharmacoecon Outcomes Res. 2017. PMID: 27658050
-
Citizen science to improve patient and public involvement in GUideline Implementation in oral health and DEntistry (the GUIDE platform).Health Expect. 2024 Feb;27(1):e13921. doi: 10.1111/hex.13921. Epub 2023 Nov 28. Health Expect. 2024. PMID: 38014917 Free PMC article.
-
A research roadmap for complementary and alternative medicine - what we need to know by 2020.Forsch Komplementmed. 2014;21(2):e1-16. doi: 10.1159/000360744. Epub 2014 Mar 24. Forsch Komplementmed. 2014. PMID: 24851850
-
Do consumer voices in health-care citizens' juries matter?Health Expect. 2016 Oct;19(5):1015-22. doi: 10.1111/hex.12397. Epub 2015 Sep 28. Health Expect. 2016. PMID: 26414486 Free PMC article. Review.
-
Eliciting public preferences for healthcare: a systematic review of techniques.Health Technol Assess. 2001;5(5):1-186. doi: 10.3310/hta5050. Health Technol Assess. 2001. PMID: 11262422
References
-
- IQVIA Institute . The Global Use of Medicine in 2019 and Outlook to 2023. January 2019. Accessed October 11, 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports/the-global-us...
-
- Sarpatwari A. Inflation reduction act and US drug pricing. BMJ. 2022;378:o2163. 10.1136/bmj.o2163 - DOI
-
- National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; Committee on Ensuring Patient Access to Affordable Drug Therapies , et al. Making Medicines Affordable: A National Imperative. National Academies Press; 2017. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical